Clinical Trials Logo

Filter by:
NCT ID: NCT06317129 Recruiting - Obesity Clinical Trials

Clinical Feasibility Study of the BariTon™ System in Obese Patients

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

Safety evaluation of BariaTek Medical gastric restriction and biliodigestive diversion device.

NCT ID: NCT06316154 Recruiting - Clinical trials for Echinococcosis, Hepatic

Presentation of Protoscolexes and Acephalocysts in the Fibrous Capsule Area of the Liver With Echinococcosis

PAFCLE
Start date: October 22, 2023
Phase:
Study type: Observational

The objective of the study is to determine the presence of germinal elements of echinococcosis in the liver parenchyma next to and in the thickness of the fibrous capsule of hydatid cysts.

NCT ID: NCT06267859 Recruiting - Clinical trials for Congenital Heart Defects

Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children

Start date: November 8, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of the clinical study is to clarify the course of common congenital, infectious, and non-infectious diseases in children living in Uzbekistan, and to develop methods for their treatment and rehabilitation. The main questions it aims to answer: - Analysis of common congenital diseases among children; - Analysis of commonly diagnosed bronchopulmonary and cardiovascular diseases among children; - Based on the results of the primary research, common diseases among children will be identified; - Analysis of existing treatment methods and their effectiveness; - Development of modern methods of treatment and rehabilitation of children.

NCT ID: NCT06169592 Recruiting - Liver Cirrhosis Clinical Trials

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation

VORTAL
Start date: April 22, 2022
Phase:
Study type: Observational

The aim of the study is to improve the results of related transplantation of the right liver lobe by verifying the general predictors of the development of hemostatic system disorders and optimizing a comprehensive program for thrombohemorrhagic complications preventing.

NCT ID: NCT06150872 Recruiting - Clinical trials for Coronary Artery Disease

Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG

Start date: January 8, 2024
Phase: N/A
Study type: Interventional

Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surgery. Study to be conducted outside the U.S.

NCT ID: NCT05990647 Completed - Incisional Hernia Clinical Trials

Impact Evaluation of Incisional Hernia on Muscular and Postural Function

IHMPF-1
Start date: January 2, 2018
Phase: N/A
Study type: Interventional

Purpose of study is to assess perioperative functional parameters of the anterior abdominal wall muscles and postural control status in patients with large and giant incisional hernias in a controlled diagnostic study. The study involved 95 patients (100% completed) with a large or giant incisional hernia of the anterior abdominal wall. The participants were divided into three groups by type of hernia repair: bridged hernia repair, Rives-Stoppa procedure, or TAR technique. Perioperative functional parameters of the anterior abdominal wall muscles were assessed by tension dynamometry. The postural balance assessments were made by raster photostereography.

NCT ID: NCT05862883 Completed - Clinical trials for COVID-19 Respiratory Infection

Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

Clinical research includes Determination of efficacy and acceptability of the local medicine "Rutan tablets 0,025" in children and teenagers 6-18 years old with COVID-19 and/or acute respiratory viral infections. And also the purpose of the study was to study clinical and laboratory changes when using Rutan in patients with Covid 19 clinical methods such as collection of anamnesis, dynamic examination of patients, catamnestic observation - a telephone survey, as well as biochemical, immunological, virologic PCR and ELISA tests.

NCT ID: NCT05859919 Completed - Clinical trials for Patients With COVID-19

Conducting Clinical Trials of the Medicine "Rutan Tablets 0.1g" No. 10 in the Complex Therapy of COVID-19

Start date: October 12, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to evaluate the efficacy and safety of the registered drug Rutan 0.1 against SARS-CoV-2 in patients with COVID-19. The main group (30 people) - patients with COVID-19 who are on inpatient treatment who were prescribed the drug Rutan 0.1, 1 tablet 2 times a day for 10 days. The control group (27 people) - patients with COVID-19 who are hospitalized and received therapy according to the National Temporary Protocol for the management of patients with COVID-19.

NCT ID: NCT05783544 Recruiting - Clinical trials for COPD Exacerbation Acute

Impact of A. Lumbricoides on Pulmonary Aspergillosis Development

Start date: May 1, 2015
Phase: N/A
Study type: Interventional

The prevalence of ascariasis in COPD patients with and without concomitant pulmonary aspergillosis and in controls will be determined. To assess the influence of ascaridosis on the development of pulmonary aspergillosis in COPD patients cytokine status of patients will be studied.

NCT ID: NCT05760625 Enrolling by invitation - Clinical trials for Primary Headache Disorder

Gender Differences and Features of the Clinical Course of Primary Headaches

Start date: December 10, 2020
Phase:
Study type: Observational [Patient Registry]

The pathophysiological mechanisms that underlie primary headache disorders, such as migraine and cluster headache (CH), are complex and not yet fully clarified. While there is today little doubt that activation of the trigeminovascular system (TGVS) is responsible for the headache pain, the primary mechanisms, probably centrally mediated, leading to its activation and the generation of pain are still largely obscure. The trigeminal system is supposed to play a central role not only in migraine but also in cluster headache pathology. In vitro studies have demonstrated the expression of BDNF in trigeminal ganglion neurons. BDNF release is induced by trigeminal stimulation and nociceptive inputs. BDNF is a member of the neurotrophin family and has been recognized as an important modulator of nociceptive pathways. Interestingly, BDNF is co-expressed with CGRP in trigeminal ganglion neurons. CGRP is one of the key molecules in migraine and cluster headache pathogenesis. BDNF is an important marker of neuronal plasticity. It has also been associated with pain processing. Increased BDNF levels are observed in chronic pain syndromes. In order to understand the role of BDNF associated with other factors such as gender on headache attacks we aimed to determine whether migraine and cluster headache is correlated with brain derived neurotrophic factor (BDNF) level, gender and age.